Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma

A. Markowitz, K. Saleemi, Leonard M. Freeman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

An immunoconjugate of the whole antibody, B72.3, has been approved by the FDA. It is labeled with indium-111, which allows imaging studies intended for the diagnosis and staging of colorectal and recurrent ovarian carcinoma. The new diagnostic imaging agent (CYT-103), Oncoscint CR/OV, has found particular use in evaluating patients with recurrent carcinoma. The three major indications for the study are: 1) occult disease-unexplained rise in serum tumor markers (e.g. CEA), with negative work-up including CT; 2) known local recurrence (e.g. liver or rectal area)-surgery is planned, but there is a need to rule out other areas of involvement; 3) clarify equivocal CT or MRI finding-to distinguish whether an abnormality is due to recurrent tumor or scar tissue, fibrosis, or unopacified bowel loop. Oncoscint has proven to be more sensitive than CT in the detection of disease in the pelvis and extrahepatic abdomen. CT remains the modality of choice for the detection of liver metastases. The combined sensitivity of the two modalities is 88% on a per-patient basis.

Original languageEnglish (US)
Pages (from-to)685-700
Number of pages16
JournalClinical Nuclear Medicine
Volume18
Issue number8
StatePublished - 1993

Fingerprint

Colorectal Neoplasms
Immunoconjugates
Carcinoma
Indium
Liver
Diagnostic Imaging
Tumor Biomarkers
Pelvis
Abdomen
Cicatrix
Fibrosis
Biomarkers
Neoplasm Metastasis
Recurrence
Indium 111In-satumomab pendetide
Neoplasms
B72.3 antibody

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma. / Markowitz, A.; Saleemi, K.; Freeman, Leonard M.

In: Clinical Nuclear Medicine, Vol. 18, No. 8, 1993, p. 685-700.

Research output: Contribution to journalArticle

@article{968868e56e934c1c907b5fb84293d8d9,
title = "Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma",
abstract = "An immunoconjugate of the whole antibody, B72.3, has been approved by the FDA. It is labeled with indium-111, which allows imaging studies intended for the diagnosis and staging of colorectal and recurrent ovarian carcinoma. The new diagnostic imaging agent (CYT-103), Oncoscint CR/OV, has found particular use in evaluating patients with recurrent carcinoma. The three major indications for the study are: 1) occult disease-unexplained rise in serum tumor markers (e.g. CEA), with negative work-up including CT; 2) known local recurrence (e.g. liver or rectal area)-surgery is planned, but there is a need to rule out other areas of involvement; 3) clarify equivocal CT or MRI finding-to distinguish whether an abnormality is due to recurrent tumor or scar tissue, fibrosis, or unopacified bowel loop. Oncoscint has proven to be more sensitive than CT in the detection of disease in the pelvis and extrahepatic abdomen. CT remains the modality of choice for the detection of liver metastases. The combined sensitivity of the two modalities is 88{\%} on a per-patient basis.",
author = "A. Markowitz and K. Saleemi and Freeman, {Leonard M.}",
year = "1993",
language = "English (US)",
volume = "18",
pages = "685--700",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma

AU - Markowitz, A.

AU - Saleemi, K.

AU - Freeman, Leonard M.

PY - 1993

Y1 - 1993

N2 - An immunoconjugate of the whole antibody, B72.3, has been approved by the FDA. It is labeled with indium-111, which allows imaging studies intended for the diagnosis and staging of colorectal and recurrent ovarian carcinoma. The new diagnostic imaging agent (CYT-103), Oncoscint CR/OV, has found particular use in evaluating patients with recurrent carcinoma. The three major indications for the study are: 1) occult disease-unexplained rise in serum tumor markers (e.g. CEA), with negative work-up including CT; 2) known local recurrence (e.g. liver or rectal area)-surgery is planned, but there is a need to rule out other areas of involvement; 3) clarify equivocal CT or MRI finding-to distinguish whether an abnormality is due to recurrent tumor or scar tissue, fibrosis, or unopacified bowel loop. Oncoscint has proven to be more sensitive than CT in the detection of disease in the pelvis and extrahepatic abdomen. CT remains the modality of choice for the detection of liver metastases. The combined sensitivity of the two modalities is 88% on a per-patient basis.

AB - An immunoconjugate of the whole antibody, B72.3, has been approved by the FDA. It is labeled with indium-111, which allows imaging studies intended for the diagnosis and staging of colorectal and recurrent ovarian carcinoma. The new diagnostic imaging agent (CYT-103), Oncoscint CR/OV, has found particular use in evaluating patients with recurrent carcinoma. The three major indications for the study are: 1) occult disease-unexplained rise in serum tumor markers (e.g. CEA), with negative work-up including CT; 2) known local recurrence (e.g. liver or rectal area)-surgery is planned, but there is a need to rule out other areas of involvement; 3) clarify equivocal CT or MRI finding-to distinguish whether an abnormality is due to recurrent tumor or scar tissue, fibrosis, or unopacified bowel loop. Oncoscint has proven to be more sensitive than CT in the detection of disease in the pelvis and extrahepatic abdomen. CT remains the modality of choice for the detection of liver metastases. The combined sensitivity of the two modalities is 88% on a per-patient basis.

UR - http://www.scopus.com/inward/record.url?scp=0027317198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027317198&partnerID=8YFLogxK

M3 - Article

C2 - 8403703

AN - SCOPUS:0027317198

VL - 18

SP - 685

EP - 700

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 8

ER -